Cochlospermum vitifolium induces vasorelaxant and antihypertensive effects mainly by activation of NO/cGMP signaling pathway

Journal of Ethnopharmacology

Volumn 130, Issue 3, 2010, Pages 477-484

  Sánchez Salgado, Juan Carlos ^a   Castillo España, Patricia ^a   Ibarra Barajas, Maximiliano ^b   Villalobos Molina, Rafael ^b   Estrada Soto, Samuel ^a  

^a UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MORELOS   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Antihypertensive; Cochlospermaceae; Cochlospermum vitifolium; Medicinal plants; Naringenin

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 2 AMINOPYRIDINE; ANTIHYPERTENSIVE AGENT; COCHLOSPERMUM VITIFOLIUM EXTRACT; CYCLIC GMP; N(G) NITROARGININE METHYL ESTER; NARINGENIN; NITRIC OXIDE; PLANT EXTRACT; TETRYLAMMONIUM; UNCLASSIFIED DRUG; FLAVANONE DERIVATIVE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; COCHLOSPERMUM VITIFOLIUM; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG STRUCTURE; ESSENTIAL HYPERTENSION; MALE; MEDICINAL PLANT; NONHUMAN; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SIGNAL TRANSDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM; VASCULAR RING; VASODILATATION; ANIMAL; BIXACEAE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERTENSION; ISOLATION AND PURIFICATION; METABOLISM; PATHOPHYSIOLOGY; THORACIC AORTA; WISTAR RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA, THORACIC; BIXACEAE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FLAVANONES; HYPERTENSION; MALE; NITRIC OXIDE; PLANT EXTRACTS; RATS; RATS, INBRED SHR; RATS, WISTAR; SIGNAL TRANSDUCTION; VASODILATOR AGENTS;

COCHLOSPERMACEAE; COCHLOSPERMUM VITIFOLIUM; RATTUS;

EID: 77954955072     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2010.05.037     Document Type: Article

References (25)

1. Ajay M., Gilani A.U., Mustafa M.R. Effects of flavonoids on vascular smooth muscle of the isolated rat thoracic aorta. Life Science 2003, 19:603-612.
2. Basile J. The role of existing and newer calcium channel blockers in the treatment of hypertension. Journal of Clinical Hypertension 2004, 6:621-629. (quiz 630-631).
3. Brett G.M., Hollands W., Needs P.W., Teucher B., Dainty J.R., Davis B.D., Brodbelt J.S., Kroon P.A. Absorption, metabolism and excretion of flavanones from single portions of orange fruit and juice and effects of anthropometric variables and contraceptive pill use on flavanone excretion. British Journal of Nutrition 2009, 101:664-675.
4. Clancy R., Varenika B., Huang W., Ballou L., Attur M., Amin A.R., Abramson S.B. Nitric oxide synthase/COX cross-talk: nitric oxide activates COX-1 but inhibits COX-2-derived prostaglandin production. Journal of Immunology 2000, 165:1582-1587.
5. Endemann D.H., Schiffrin E.L. Endothelial dysfunction. Journal of the American Society Nephrology 2004, 15:1983-1992.
6. Erdine S., Ari O., Zanchetti A., Cifkova R., Fagard R., Kjeldsen S., Mancia G., Poulter N., Rahn K.H., Rodicio J.L., Ruilope L.M., Staessen J., van Zwieten P., Waeber B., Williams B. ESH-ESC guidelines for the management of hypertension. Herz 2006, 31:331-338.
7. Felgines C., Texier O., Morand C., Manach C., Scalbert A., Régerat F., Rémésy C. Bioavailability of the flavanone naringenin and its glycosides in rats. American Journal of Physiology. Gastrointestinal and Liver Physiology 2000, 279:G1148-G1154.
8. G-monoethyl-l-arginine or NG-nitro-l-arginine-methyl ester in conscious Brattleboro rats. British Journal of Pharmacology 1990, 101:10-12.
9. Herrera M.D., Zarzuelo A., Jiménez J., Marhuenda E., Duarte J. Effects of flavonoids on rat aortic smooth muscle contractility: structure-activity relationships. General Pharmacology 1996, 27:273-277.
10. Hodgson J.M., Puddey I.B., Burke V., Croft K.D. Is reversal of endothelial dysfunction by tea related to flavonoid metabolism?. British Journal of Nutrition 2006, 95:14-17.
11. Hollman P.C., Katan M.B. Dietary flavonoids: intake, health effects and bioavailability. Food and Chemical Toxicology 1999, 37:937-942.
12. Koehn F.E., Carter G.T. The evolving role of natural products in drug discovery. Nature Reviews Drug Discovery 2005, 4:206-220.
13. Lagrue-Lak-Hal A.H., Andriantsitohaina R. Red wine and cardiovascular risk. Archives des Maladies du Coeur et des Vaisseaux 2006, 99:1230-1235.
14. Li H., Forstermann U. Nitric oxide in the pathogenesis of vascular disease. Journal of Pathology 2000, 190:244-254.
15. Liu L., Xu D.M., Cheng Y.Y. Distinct effects of naringenin and hesperetin on nitric oxide production from endothelial cells. Journal of Agricultural and Food Chemistry 2008, 56:824-829.
16. Monroy-Ortiz C., Castillo-España P. Plantas medicinales utilizadas en el Estado de Morelos 2007 2007, Centro de Investigaciones Biológicas, Universidad Autónoma del Estado de Morelos.
17. Orallo F., Camiña M., Alvarez E., Basaran H., Lugnier C. Implication of cyclic nucleotide phosphodiesterase inhibition in the vasorelaxant activity of the citrus-fruits flavonoid (+/-)-naringenin. Planta Medica 2005, 71:99-107.
18. Russell J.C., Proctor S.D. Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovascular Pathology 2006, 15:318-330.
19. Sánchez-Salgado J.C., Ortiz-Andrade R.R., Aguirre-Crespo F.J., Vergara-Galicia J., Leon-Rivera I., Montes S., Villalobos-Molina R., Estrada-Soto S. Hypoglycemic, vasorelaxant and hepatoprotective effects of Cochlospermum vitifolium (Willd.) Sprengel: a potential agent for the treatment of metabolic syndrome. Journal of Ethnopharmacology 2007, 109:400-405.
20. + (BKCa) channel opener in vascular smooth muscle cells. British Journal of Pharmacology 2006, 149:1013-1021.
21. Schlossmann J., Feil R., Hofmann F. Signaling through NO and cGMP-dependent protein kinases. Annals of Medicine 2003, 35:21-27.
22. Sharma V., McNeill J.H. The etiology of hypertension in the metabolic syndrome part one: an introduction to the history, the concept and the models. Current Vascular Pharmacology 2006, 4:293-304.
23. Torres-Piedra M., Ortiz-Andrade R., Villalobos-Molina R., Singh N., Medina-Franco J.L., Webster S.P., Binnie M., Navarrete-Vazquez G., Estrada-Soto S. A comparative study of flavonoid analogues on streptozotocin-nicotinamide induced diabetic rats: quercetin as a potential antidiabetic agent acting via 11beta-hydroxysteroid dehydrogenase type 1 inhibition. European Journal of Medicinal Chemistry 2010, 45:2606-2612.
24. Vergara-Galicia J., Ortiz-Andrade R., Castillo-España P., Ibarra-Barajas M., Gallardo-Ortiz I., Villalobos-Molina R., Estrada-Soto S. Antihypertensive and vasorelaxant activities of Laelia autumnalis are mainly through calcium channel blockade. Vascular Pharmacology 2008, 49:26-31.
25. World Health Organization Prevention of Cardiovascular Disease: Pocket Guidelines for Assessment and Management of Cardiovascular Risk 2007, Available at, (accessed 12.1.2009). http://www.who.int/cardiovascular_diseases/guidelines/Pocket_GL_information/en/index.html.